Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02099539 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT02099539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02099539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Altor BioScience
Phase
Phase 1
Overall status
Terminated
Start date
October 6, 2014
Completion date
June 19, 2018
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma